Riobaldo M. R. Cintra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Riobaldo M. R. Cintra has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Carvalho Sposito
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, Brazil
15 shared publications - Luiz Sérgio Fernandes de Carvalho
Universidade Católica de Brasília, Brasil
11 shared publications Jose C. Quinaglia e Silva
Hospital de Base do Distrito Federal, Brasília, Brazil
7 shared publications- Filipe Azevedo Moura
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; VA Connecticut Healthcare System, West Haven, CT
5 shared publications - Wilson Nadruz
Department of Internal Medicine, School of Medical Sciences, State University of Campinas
5 shared publications - Otávio Rizzi Coelho
Universidade Estadual de Campinas
4 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in Diabetes & Metabolism
- Vol. 47 (6) , 101280
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial
- 1 November 2021
- Published by Elsevier in Diabetes & Metabolism
- Vol. 47 (6) , 101280
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial
- Open Access
- 8 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
Hyperglycemia during myocardial infarction (MI) has a strong and direct association with mortality. In stable patients and experimental models, statins favor the elevation of glycaemia. The present study investigated whether short-course treatment with statins during MI can influence glucose homeostasis and thus the clinical outcome. In this prospective study, euglycemic hyperinsulinemic clamp (EHC) was performed at second (D2) and sixth (D6) day after MI in patients randomized to simvastatin (S)10 or 80 mg/day during hospitalization (n = 27). In addition, patients (n = 550) were treated without (WS) or with simvastatin (S) at 20, 40 or 80 mg/day had HOMA2S on admission (D1) and fifth (D5) day after MI. According to EHC, insulin sensitivity increased by 20 ± 60% in S10 and decreased by −6 ± 28% in S80 (p = 0.025). Consistently, the changes in HOMA2S between D1 and D5 were 40 ± 145% (WS), 22 ± 117% (S20), 16 ± 61% (S40) and −2% ± 88% (S80) (p = 0.001). In conclusion, statin during the acute phase of MI reduces insulin sensitivity in a dose-dependent manner.
- 8 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Open AccessStatin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
Hyperglycemia during myocardial infarction (MI) has a strong and direct association with mortality. In stable patients and experimental models, statins favor the elevation of glycaemia. The present study investigated whether short-course treatment with statins during MI can influence glucose homeostasis and thus the clinical outcome. In this prospective study, euglycemic hyperinsulinemic clamp (EHC) was performed at second (D2) and sixth (D6) day after MI in patients randomized to simvastatin (S)10 or 80 mg/day during hospitalization (n = 27). In addition, patients (n = 550) were treated without (WS) or with simvastatin (S) at 20, 40 or 80 mg/day had HOMA2S on admission (D1) and fifth (D5) day after MI. According to EHC, insulin sensitivity increased by 20 ± 60% in S10 and decreased by −6 ± 28% in S80 (p = 0.025). Consistently, the changes in HOMA2S between D1 and D5 were 40 ± 145% (WS), 22 ± 117% (S20), 16 ± 61% (S40) and −2% ± 88% (S80) (p = 0.001). In conclusion, statin during the acute phase of MI reduces insulin sensitivity in a dose-dependent manner.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (1) , 87-97
Central role of obesity in endothelial cell dysfunction and cardiovascular risk
SUMMARY Atherosclerosis is the leading cause of mortality in the contemporary world. The critical role of the endothelial cells (EC) in vascular homeostasis, the metabolic changes that take place when the cell is activated, and the elements involved in these processes have been widely explored over the past years. Obesity and its impact, promoting a rise in blood levels of free fatty acids (FAs) are often associated with atherosclerosis and cardiovascular mortality. However, the mechanisms that promote cardiovascular structural changes and adaptive changes in the ECs, particularly in the context of obesity, are little known. Here, we reviewed studies that assessed the metabolic adaptations of healthy and dysfunctional ECs during exposure to FAs, as well as the epidemiological perspectives of cardiovascular structural changes in obesity. Finally, we explored the role of new agents – sphingolipids, dietary unsaturated fatty acids and sodium-glucose cotransporter-2 inhibitors (iSGLT2) – in atherosclerosis and their relationship with obesity.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (1) , 87-97
Open AccessCentral role of obesity in endothelial cell dysfunction and cardiovascular risk
SUMMARY Atherosclerosis is the leading cause of mortality in the contemporary world. The critical role of the endothelial cells (EC) in vascular homeostasis, the metabolic changes that take place when the cell is activated, and the elements involved in these processes have been widely explored over the past years. Obesity and its impact, promoting a rise in blood levels of free fatty acids (FAs) are often associated with atherosclerosis and cardiovascular mortality. However, the mechanisms that promote cardiovascular structural changes and adaptive changes in the ECs, particularly in the context of obesity, are little known. Here, we reviewed studies that assessed the metabolic adaptations of healthy and dysfunctional ECs during exposure to FAs, as well as the epidemiological perspectives of cardiovascular structural changes in obesity. Finally, we explored the role of new agents – sphingolipids, dietary unsaturated fatty acids and sodium-glucose cotransporter-2 inhibitors (iSGLT2) – in atherosclerosis and their relationship with obesity.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (1) , 70-86
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
SUMMARY The prevalence of type 2 diabetes mellitus (T2DM) in the elderly grew sharply over the last decade. Reduced insulin sensitivity and secretory capacity, weight gain, sarcopenia, and elevated adiposity are all common metabolic and body changes in the aging population that favor an increased risk of hypoglycemia, frailty syndrome, falls, and cognitive dysfunction. First line antidiabetic therapy is frequently not safe in older individuals because of its high risk of hypoglycemia and prevalent co-morbid diseases, such as chronic kidney disease, osteoporosis, cardiovascular disease, and obesity. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of antidiabetic therapy that inhibits glucose and sodium reabsorption on renal proximal convoluted tubule. Its effect is well demonstrated in various clinical scenarios in the younger population. This review and metanalysis describe particularities of the SGLT2i on the elderly, with mechanistic insights of the potential benefit and remaining challenges about the use of these drugs in this important age group. Further, we will present a meta-analysis of the main effects of SGLT2i reported in post-hoc studies in which the median age of the subgroups analyzed was over 60 years. Despite the absence of specific clinical trials for this population, our findings suggest that SGLT2i therapy on older individuals is effective to lower glucose and maintain its effect on systolic blood pressure and body weight.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (1) , 70-86
Open AccessInhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
SUMMARY The prevalence of type 2 diabetes mellitus (T2DM) in the elderly grew sharply over the last decade. Reduced insulin sensitivity and secretory capacity, weight gain, sarcopenia, and elevated adiposity are all common metabolic and body changes in the aging population that favor an increased risk of hypoglycemia, frailty syndrome, falls, and cognitive dysfunction. First line antidiabetic therapy is frequently not safe in older individuals because of its high risk of hypoglycemia and prevalent co-morbid diseases, such as chronic kidney disease, osteoporosis, cardiovascular disease, and obesity. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of antidiabetic therapy that inhibits glucose and sodium reabsorption on renal proximal convoluted tubule. Its effect is well demonstrated in various clinical scenarios in the younger population. This review and metanalysis describe particularities of the SGLT2i on the elderly, with mechanistic insights of the potential benefit and remaining challenges about the use of these drugs in this important age group. Further, we will present a meta-analysis of the main effects of SGLT2i reported in post-hoc studies in which the median age of the subgroups analyzed was over 60 years. Despite the absence of specific clinical trials for this population, our findings suggest that SGLT2i therapy on older individuals is effective to lower glucose and maintain its effect on systolic blood pressure and body weight.
- 1 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 254, 16-22
Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction
- 1 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 254, 16-22
Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction
- 27 December 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 88 (3) , 388-396
Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects
Summary: Background: The combinations of adipokines and body mass parameters to estimate carotid atherosclerotic disease have not been completely delineated.Objective: To test the combinations of well‐established, easily accessible body mass indices and circulating biomarkers to identify increased carotid intima‐media thickness (cIMT) in a primary prevention setting.Design and patients: In a cross‐sectional analysis of 339 asymptomatic individuals with no history of cardiovascular events, inflammatory and insulin sensitivity biomarkers as well as adipokine levels were measured and combined with body mass parameters to evaluate the best marker for increased cIMT.Results: As isolated parameters, body mass index (BMI) and adiponectin best identified abnormal cIMT (P = .04). Adiponectin levels were also linked to the relationship between BMI and cIMT (β = 0.0371; P = .01). Twenty‐nine individuals with increased cIMT were missed by BMI alone but detected by combining BMI and adiponectin measurements. When compared with BMI alone, the combination of adiponectin plus BMI improved the c‐statistic (0.549‐0.567) and the integrated discrimination improvement index (0.01725; P = .021). Segregation of individuals by the combined use of BMI + adiponectin is associated with significant differences in insulin sensitivity, glomerular filtration rate, systemic inflammatory activity, dyslipidaemia and cIMT.Conclusions: Combining plasma adiponectin measurements and BMI improves estimation of cIMT as compared to anthropometric parameters.
- 27 December 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 88 (3) , 388-396
Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects
Summary: Background: The combinations of adipokines and body mass parameters to estimate carotid atherosclerotic disease have not been completely delineated.Objective: To test the combinations of well‐established, easily accessible body mass indices and circulating biomarkers to identify increased carotid intima‐media thickness (cIMT) in a primary prevention setting.Design and patients: In a cross‐sectional analysis of 339 asymptomatic individuals with no history of cardiovascular events, inflammatory and insulin sensitivity biomarkers as well as adipokine levels were measured and combined with body mass parameters to evaluate the best marker for increased cIMT.Results: As isolated parameters, body mass index (BMI) and adiponectin best identified abnormal cIMT (P = .04). Adiponectin levels were also linked to the relationship between BMI and cIMT (β = 0.0371; P = .01). Twenty‐nine individuals with increased cIMT were missed by BMI alone but detected by combining BMI and adiponectin measurements. When compared with BMI alone, the combination of adiponectin plus BMI improved the c‐statistic (0.549‐0.567) and the integrated discrimination improvement index (0.01725; P = .021). Segregation of individuals by the combined use of BMI + adiponectin is associated with significant differences in insulin sensitivity, glomerular filtration rate, systemic inflammatory activity, dyslipidaemia and cIMT.Conclusions: Combining plasma adiponectin measurements and BMI improves estimation of cIMT as compared to anthropometric parameters.
- Open Access
- 1 June 2016
- Published by Elsevier in BBA Clinical
- Vol. 5, 159-165
TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction
- 1 June 2016
- Published by Elsevier in BBA Clinical
- Vol. 5, 159-165
Open AccessTCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction
- 1 November 2015
- Published by Elsevier in Atherosclerosis
- Vol. 243 (1) , 124-130
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
- 1 November 2015
- Published by Elsevier in Atherosclerosis
- Vol. 243 (1) , 124-130
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
- Open Access
- 1 June 2015
- Published by Elsevier in BBA Clinical
- Vol. 3, S13
HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk
- 1 June 2015
- Published by Elsevier in BBA Clinical
- Vol. 3, S13
Open AccessHDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk
- Open Access
- 1 June 2015
- Published by Elsevier in BBA Clinical
- Vol. 3, S4
The hypertension paradox: ACE inhibitors or ARB attenuate mortality in hypertensive patients undergoing myocardial infarction
- 1 June 2015
- Published by Elsevier in BBA Clinical
- Vol. 3, S4
Open AccessThe hypertension paradox: ACE inhibitors or ARB attenuate mortality in hypertensive patients undergoing myocardial infarction